Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

310 results found

2013 ∙ ACIP

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions

  • Recommendation
  • Americas
  • United States of America
  • Pneumococcal disease
Download:
2012 ∙ Cadeddu, C. De Waure, C. Gualano, M. R. Di Nardo, F. Ricciardi, W.

23-valent pneumococcal polysaccharide vaccine (PPV23) for the prevention of invasive pneumococcal diseases (IPDs) in the elderly: Is it really effective?

  • Older adults
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2012 ∙ Agarwal, N. Ollington, K. Kaneshiro, M. Frenck, R. Melmed, G. Y.

Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review

  • All age groups
  • Influenza
  • Pneumococcal disease
  • Meningococcal disease
  • Hepatitis A
  • Hepatitis B
  • Tetanus
  • Pertussis
  • Varicella
  • Herpes zoster
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2012 ∙ El-Makhzangy, A. M. Ismail, N. M. Galal, S. B. Sobhy, T. S. Hegazy, A. A.

Can vaccination against pneumococci prevent otitis media with effusion?

  • Newborn
  • Children
  • Adolescents
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2012 ∙ Farkouh, R. A. Klok, R. M. Postma, M. J. Roberts, C. S. Strutton, D. R.

Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions

  • All age groups
  • Pneumococcal disease
  • Economic aspects
  • Coverage
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Not applicable
2012 ∙ Taylor, S. Marchisio, P. Vergison, A. Harriague, J. Hausdorff, W. P. Haggard, M.

Impact of pneumococcal conjugate vaccination on otitis media: A systematic review

  • Newborn
  • Children
  • Adolescents
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2012 ∙ Sehatzadeh, S.

Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): an evidence-based review

  • Adults
  • Older adults
  • Influenza
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2012 ∙ Lau, D. Hu, J. Majumdar, S. R. Storie, D. A. Rees, S. E. Johnson, J. A.

Interventions to improve influenza and pneumococcal vaccination rates among community-dwelling adults: a systematic review and meta-analysis

  • Adults
  • Older adults
  • Influenza
  • Pneumococcal disease
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2012 ∙ Makris, M. C. Polyzos, K. A. Mavros, M. N. Athanasiou, S. Rafailidis, P. I. Falagas, M. E.

Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: A systematic review

  • Pregnant women
  • Meningococcal disease
  • Hepatitis B
  • Pneumococcal disease
  • Safety
Methodological quality (AMSTAR 2):
Critically low
Loading...